Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prime Medicine (PRME) Cash & Equivalents (2021 - 2025)

Prime Medicine filings provide 5 years of Cash & Equivalents readings, the most recent being $63.0 million for Q4 2025.

  • On a quarterly basis, Cash & Equivalents fell 65.46% to $63.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $63.0 million, a 65.46% decrease, with the full-year FY2025 number at $63.0 million, down 65.46% from a year prior.
  • Cash & Equivalents hit $63.0 million in Q4 2025 for Prime Medicine, down from $71.4 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $200.7 million in Q3 2021 to a low of $41.6 million in Q4 2023.
  • Median Cash & Equivalents over the past 5 years was $92.1 million (2022), compared with a mean of $100.7 million.
  • Biggest five-year swings in Cash & Equivalents: plummeted 77.84% in 2023 and later soared 338.92% in 2024.
  • Prime Medicine's Cash & Equivalents stood at $49.5 million in 2021, then soared by 279.03% to $187.6 million in 2022, then plummeted by 77.84% to $41.6 million in 2023, then skyrocketed by 338.92% to $182.5 million in 2024, then crashed by 65.46% to $63.0 million in 2025.
  • The last three reported values for Cash & Equivalents were $63.0 million (Q4 2025), $71.4 million (Q3 2025), and $53.8 million (Q2 2025) per Business Quant data.